Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer

Angelo Carretta, Paola Ciriaco, Giulio Melloni, Imad Sayed, Alessandro Bandiera, Luca Ferla, Armando Puglisi, Piero Zannini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The potential benefits of an approach combining neoadjuvant chemotherapy and surgery in stage IIIA and IIIB NSCLC have to be weighed against a potential increase in postoperative complications. We evaluated the results in terms of postoperative complications and survival in patients with stage III NSCLC who underwent complete surgical treatment after neoadjuvant chemotherapy with two regimens: mitomycin, vinblastine, and cisplatin (MPV) versus gemcitabine and cisplatin (GC). Methods: From March 1991 to September 2005, 110 patients with stage III NSCLC (86 stage IIIA and 24 stage IIIB) underwent complete surgical treatment after neoadjuvant chemotherapy. Ninety-two patients were men and 18 were women, with a mean age of 59 (range, 39-80) years. The neoadjuvant chemotherapy regimen was MPV in 72 patients and GC in 38. Results: The overall response (>50%) to chemotherapy was 84%. Postoperative mortality and morbidity were 1.8% and 20%, respectively. Overall 5-year survival was 46%. Minor response to neoadjuvant chemotherapy (

Original languageEnglish
Pages (from-to)2636-2642
Number of pages7
JournalWorld Journal of Surgery
Volume32
Issue number12
DOIs
Publication statusPublished - Dec 2008

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this